Drug Discovery World

SEPTEMBER 6, 2022

Unsurprisingly, oncology remains the biggest focus for cell and gene therapy developers, accounting for 52% of clinical activity in 2021, according to ARM’s Regenerative Medicine: Disrupting the Status Quo report. Last year saw the sector surge, with levels of investment hitting an all-time high at $22.7 billion, compared to $19.9

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

NOVEMBER 13, 2023

On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific antibodies, next-generation immunotherapies, protein stability and formulation, and protein process development.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK.

Antibody 59

Antibody Protein Engineer In-Vivo 59